secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001628280-23-027426
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics Q2 net loss $12.4M; OV329 SAD complete; Graviton ROCK2 collaboration
--------------------------------------------------------------------------------

- Cash and securities $96.5M as of June 30, 2023; net loss $0.18 per share vs $0.21 year ago.
- OV329 Phase 1 single-ascending-dose portion completed with no safety signals; full data expected H1 2024.
- Entered license/collaboration with Graviton for ROCK2 inhibitors with $10M equity investment.
- Appointed Dr. Zhong Zhong CSO and Dr. Manoj Malhotra CMO; Meg Alexander promoted to Chief Strategy Officer.
- Implemented cost-cutting measures including G&A headcount reduction; cash runway expected into 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828023027426/0001628280-23-027426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828023027426/ovid-20230804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-027426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer